Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women of non-child bearing potential,~* Between the ages of 18 and 55 inclusive,~* Body mass index from 18 to 33 kg/m2,~* Skin type compatible with the study assessments, and without significant skin allergies, pigmentary disorders, tattoos, or any active dermatologic conditions that might interfere with the study conduct.~Exclusion Criteria:~* Prior or current history of peripheral neuropathy, paraesthesias, dysesthesias, herpes zoster, post-herpetic neuralgia,~* Evidence of any current illness such as a common cold, viral syndrome, or flu-like symptoms, any disturbance of the autonomic nervous system,~* History of Raynaud's phenomenon; Know allergy or intolerance to capsaicin or hot peppers.

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AMG 403 (Type: EXPERIMENTAL): AMG 403 administered as subcutaneous and intravenous doses
- Placebo (Type: PLACEBO_COMPARATOR): No active drug

Based on this trial design, predict the completion outcome and termination type (if applicable).